Evaluation of anthrax vaccine production by Bacillus anthracis Sterne 34F2 in stirred suspension culture using a miniature bioreactor: A useful scale-down tool for studies on fermentations at high containment

Biochemical Engineering Journal

Volumn 50, Issue 3, 2010, Pages 139-144

  Mukhopadhyay, Tarit K ^a   Allison, Nigel ^b   Charlton, Susan ^b   Hudson, Michael J ^b   Hallis, Bassam ^b   King, Annemarie ^b   Baker, Rebecca ^b   Noonan, Sara ^b   McGlashan, Joanne ^b   West, Katie ^b   Levy, M Susana ^a   Ward, John M ^a   Lye, Gary J ^a  

^a UNIVERSITY COLLEGE LONDON   (United Kingdom)

^b PUBLIC HEALTH ENGLAND   (United Kingdom)

Author keywords

Anthrax vaccine; Bacillus anthracis Sterne 34F2; Lethal Factor (LF); Miniature bioreactor; Protective Antigen (PA)

Indexed keywords

ANTHRAX VACCINES; BACILLUS ANTHRACIS STERNE; LETHAL FACTOR; MINIATURE BIOREACTOR; PROTECTIVE ANTIGENS;

ANTIGENS; BACTERIOLOGY; BIOCONVERSION; BIOREACTORS; CELL CULTURE; GLASS BOTTLES; INVESTMENTS;

VACCINES;

ANTHRAX VACCINE; BACTERIAL ANTIGEN;

AERATION; ARTICLE; BACILLUS ANTHRACIS; BACTERIAL KINETICS; BATCH FERMENTATION; CELL DENSITY; CONCENTRATION (PARAMETERS); CONTROLLED STUDY; COST CONTROL; FERMENTATION OPTIMIZATION; INTERMETHOD COMPARISON; LETHAL GENE; NONHUMAN; PRIORITY JOURNAL; PROCESS DEVELOPMENT; PROCESS MODEL; PROTEIN DEGRADATION; REACTOR OPERATION; STIRRED REACTOR; SUSPENSION CELL CULTURE; VACCINE PRODUCTION;

BACILLUS ANTHRACIS STR. STERNE;

EID: 77952242789     PISSN: 1369703X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.bej.2010.03.011     Document Type: Article

References (35)

1. Kostov Y., Harms P., Randers-Eichhorn L., and Rao G. Low-cost microbioreactor for high-throughput bioprocessing. Biotechnol. Bioeng. 72 (2001) 346-352
2. Kumar S., Wittmann C., and Heinzle E. Minibioreactors. Biotechnol. Lett. 26 (2004) 1-10
3. Lye G.J., Ayazi-Shamlou P., Baganz F., Dalby P.A., and Woodley J.M. Accelerated design of bioconversion processes using automated microscale processing techniques. Trends Biotechnol. 21 (2003) 29-37
4. Puskeiler R., Kusterer A., John G.T., and Weuster-Botz D. Miniature bioreactors for automated high-throughput bioprocess design (HTBD): reproducibility of parallel fed-batch cultivations with Escherichia coli. Biotechnol. Appl. Biochem. 42 (2005) 227-235
5. Micheletti M., and Lye G.J. Microscale bioprocess optimisation. Curr. Opin. Biotechnol. 17 (2006) 611-618
6. Betts J., Doig S.D., and Baganz F. Characterization and application of a miniature 10 mL stirred-tank bioreactor, showing scale-down equivalence with a conventional 7 L reactor. Biotechnol. Prog. 22 (2006) 681-688
7. Doig S.D., Avenell P.J., Bird P.A., Gallati P., Lander K.S., Lye G.J., Wohlgemuth R., and Woodley J.M. Reactor operation and scale-up of whole cell Baeyer-Villiger catalyzed lactone synthesis. Biotechnol. Prog. 18 (2002) 1039-1046
8. Brachman P.S. Bioterrorism: an update with a focus on anthrax. Am. J. Epidemiol. 155 (2002) 981-987
9. Mock M., and Fouet A. Anthrax. Annu. Rev. Microbiol. 55 (2001) 647-671
10. Wenner K.A., and Kenner J.R. Anthrax. Derm. Clin. 22 (2004) 247-256
11. Guidi-Rontani C., Weber-Levy M., Labruyère E., and Mock M. Germination of Bacillus anthracis spores within alveolar macrophages. Mol. Microbiol. 31 (1999) 9-17
12. Beall F.A., Taylor M.J., and Thorne C.B. Rapid lethal effect in rats of a third component found upon fractionating the toxin of Bacillus anthracis. J. Bacteriol. 83 (1962) 1274-1280
13. Stanley J.L., and Smith H. Purification of factor I and recognition of a third factor of the anthrax toxin. J. Gen. Microbiol. 26 (1961) 49-63
14. Zwartouw H.T., and Smith H. Polyglutamic acid from Bacillus anthracis grown in vivo; structure and aggression activity. Biochem. J. 63 (1956) 437-442
15. Grabenstein J.D. Anthrax vaccine: a review. Immunol. Allergy Clin. N Am. 23 (2003) 713-730
16. Laughlin E.M., Miller J.D., James E., Fillos D., Ibegbu C.C., Mittler R.S., Akondy R., Kwok W., Ahmed R., and Nepom G. Antigen-specific CD4+ T cells recognize epitopes of protective antigen following vaccination with an anthrax vaccine. Infect. Immun. 75 (2007) 1852-1860
17. Duesbery N.S., Webb C.P., Leppla S.H., Gordon V.M., Klimpel K.R., Copeland T.D., Ahn N.G., Oskarsson M.K., Fukasawa K., Paull K.D., and Vande Woude G.F. Proteolytic inactivation of MAP-kinase-kinase by anthrax lethal factor. Science 280 (1998) 734-737
18. Leppla S.H. Bacillus anthracis calmodulin-dependent adenylate cyclase: chemical and enzymatic properties and interactions with eucaryotic cells. Adv. Cyclic Nucleotide Protein Phosphorylation Res. 17 (1984) 189-198
19. Mock M., and Mignot T. Anthrax toxins and the host: a story of intimacy. Cell. Microbiol. 5 (2003) 15-23
20. Sirard J.C., Mock M., and Fouet A. The three Bacillus anthracis toxin genes are coordinately regulated by bicarbonate and temperature. J. Bacteriol. 176 (1994) 5188-5192
21. Uchida I., Hornung J.M., Thorne C.B., Klimpel K.R., and Leppla S.H. Cloning and characterization of a gene whose product is a trans-activator of anthrax toxin synthesis. J. Bacteriol. 175 (1993) 5329-5338
22. Uchida I., Makino S., Sekizaki T., and Terakado N. Cross-talk to the genes for Bacillus anthracis capsule synthesis by atxA, the gene encoding the trans-activator of anthrax toxin synthesis. Mol. Microbiol. 23 (1997) 1229-1240
23. Hambleton P., Carman J.A., and Melling J. Anthrax: the disease in relation to vaccines. Vaccine 2 (1984) 125-132
24. Gill N.K., Appleton M., Baganz F., and Lye G.J. Design and characterisation of a miniature stirred bioreactor system for parallel microbial fermentations. Biochem. Eng. J. (2008)
25. Gill N.K., Appleton M., Baganz F., and Lye G.J. Quantification of power consumption and oxygen transfer characteristics of a stirred miniature bioreactor for predictive fermentation scale-up. Biotechnol. Bioeng. 100 (2008) 1144-1155
26. Charlton S., Herbert M., Mcglashan J., King A., Jones P., West K., Roberts A., Silman N., Marks T., Hudson M., and Hallis B. A study of the physiology of Bacillus anthracis Sterne during manufacture of the UK acellular anthrax vaccine. J. Appl. Microbiol. 103 (2007) 1453-1460
27. Hoffmaster A.R., and Koehler T.M. The anthrax toxin activator gene atxA is associated with CO2-enhanced non-toxin gene expression in Bacillus anthracis. Infect. Immun. 65 (1997) 3091-3099
28. Hoffmaster A.R., and Koehler T.M. Control of virulence gene expression in Bacillus anthracis. J. Appl. Microbiol. 87 (1999) 279-281
29. Mignot T., Mock M., and Fouet A. A plasmid-encoded regulator couples the synthesis of toxins and surface structures in Bacillus anthracis. Mol. Microbiol. 47 (2003) 917-927
30. Miller C., Elliott J., and Collier R. Anthrax protective antigen: prepore-to-pore conversion. Biochemistry 38 (1999) 10432-10441
31. Thomas C.R., and Dunnill P. Action of shear on enzymes: studies with catalase and urease. Biotechnol. Bioeng. 21 (1979) 2279-2302
32. Hoare M., and Dunnill P. Biochemical engineering challenges of purifying useful proteins. Philos. Trans. R. Soc. Lond. B: Biol. Sci. 324 (1989) 497-507
33. Virkar P.D., Narendranathan T.J., Hoare M., and Dunnill P. Studies of the effect of shear on globular proteins: extension to high shear fields and to pumps. Biotechnol. Bioeng. (1981)
34. Keane J.T., Ryan D., and Gray P.P. Effect of shear stress on expression of a recombinant protein by Chinese hamster ovary cells. Biotechnol. Bioeng. 81 (2003) 211-220
35. Hepler R.W., Kelly R., Mcneely T.B., Fan H., Losada M.C., George H.A., Woods A., Cope L.D., Bansal A., Cook J.C., Zang G., Cohen S.L., Wei X., Keller P.M., Leffel E., Joyce J.G., Pitt L., Schultz L.D., Jansen K.U., and Kurtz M. A recombinant 63-kDa form of Bacillus anthracis protective antigen produced in the yeast Saccharomyces cerevisiae provides protection in rabbit and primate inhalational challenge models of anthrax infection. Vaccine 24 (2006) 1501-1514